This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Cheiljedang Corp., Cj Cheiljedang Corporation. Active years: 2006-2011.
Company Filing History:
Years Active: 2006-2011
Title: Bo-Sup Chung: Innovator in Fusion Protein Technology
Introduction
Bo-Sup Chung is a notable inventor based in Anyang, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of fusion proteins. With a total of 2 patents, his work focuses on enhancing the therapeutic efficacy of erythropoietin.
Latest Patents
Chung's latest patents include innovative fusion proteins that improve the in vivo activity of erythropoietin. The first patent describes a fusion protein where the carboxy terminal of human erythropoietin (EPO) is fused with a carboxy terminal peptide fragment of the β subunit of human chorionic gonadotropin (HCG). This invention aims to enhance the in vivo activity of erythropoietin. The second patent also relates to a fusion protein that has an enhanced in vivo activity of erythropoietin. In this case, a carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal of human erythropoietin. This fusion protein boasts a highly enhanced in vivo half-life due to increased carbohydrate content, while maintaining the inherent activity of erythropoietin and avoiding antigenicity when applied to the human body.
Career Highlights
Throughout his career, Bo-Sup Chung has worked with prominent companies in the biotechnology sector, including Cheiljedang Corp. and CJ Cheiljedang Corporation. His experience in these organizations has contributed to his expertise in protein engineering and therapeutic development.
Collaborations
Chung has collaborated with notable colleagues such as Dong-Eok Lee and Ji-Sook Park. These partnerships have likely facilitated the advancement of his research and innovations in the field.
Conclusion
Bo-Sup Chung is a distinguished inventor whose work in fusion protein technology has the potential to significantly impact therapeutic applications. His innovative patents reflect his commitment to enhancing the efficacy of important biological treatments.